Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy
- 28 July 2002
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 269 (1-2) , 269-281
- https://doi.org/10.1016/s0022-1759(02)00241-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A Convenient Synthesis of N,N-Bis(2-chloroethyl)-p-aminophenylacetic Acid, a Major Metabolite of the Cancer Chemotherapeutic Agent Chlorambucil.Acta Chemica Scandinavica, 1996
- Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugatesTrends in Biotechnology, 1994
- Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACsNature Genetics, 1994
- Antibody-Catalyzed Prodrug ActivationJournal of the American Chemical Society, 1994
- Novel anticancer prodrugs of butyric acid. 2Journal of Medicinal Chemistry, 1992
- Use of the 3T3 cell-neutral red uptake assay for irritants as an alternative to the rabbit (Draize) testFood and Chemical Toxicology, 1986
- Butyric acid: A small fatty acid with diverse biological functionsLife Sciences, 1980
- Synthesis and antitumor activity of 4-[p-[bis(2-chloroethyl)amino]phenyl]butyratesJournal of Pharmaceutical Sciences, 1980
- Nonsteroidal Anti-Inflammatory AgentsAnnual Review of Pharmacology and Toxicology, 1979
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975